CSS LLC’s Seres Therapeutics MCRB Stock Holding History

CSS LLC’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-490	Closed	-$234K	–	1251
2021 Q2	$234K	Buy	+490	New	+$207K	0.01%	816

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSS LLC's MCRB Position: Q3 2021 in Review

CSS LLC sold out of Seres Therapeutics (MCRB) in Q3 2021, closing a stake of 2,212 shares — an estimated $1.05M sold.

CSS LLC first reported a position in MCRB in Q2 2021 and held it in 1 quarter. The position peaked at $1.05M in Q2 2021. 133 funds tracked by Wall St. Rank hold MCRB as of Q3 2021.

CSS LLC reported no remaining Seres Therapeutics position as of Q3 2021 after selling out during the quarter.
CSS LLC sold 2,212 Seres Therapeutics shares in Q3 2021, an estimated $1.05M.
CSS LLC first reported a position in Seres Therapeutics in Q2 2021 and held it in 1 quarter.
CSS LLC's Seres Therapeutics position peaked at $1.05M in Q2 2021.
133 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2021.

Based on CSS LLC's 13F filing for Q3 2021, filed 15 Nov 2021.